Homograft aortic root replacement in native or prosthetic active infective endocarditis: Twenty-year single-center experience  by Musci, Michele et al.
Musci et al Acquired Cardiovascular DiseaseHomograft aortic root replacement in native or prosthetic active
infective endocarditis: Twenty-year single-center experienceMichele Musci, MD, Yuguo Weng, MD, PhD, Michael Hu¨bler, MD, Aref Amiri, MD, Miralem Pasic, MD, PhD,
Susanne Kosky, Julia Stein, MSc, Henryk Siniawski, MD, PhD, and Roland Hetzer, MD, PhDFrom th
Surge
Disclos
This pa
Lisbo
Receive
publi
Address
Berlin
1, 13
0022-52
Copyrig
doi:10.1
A
C
DObjective: We compared early and long-term results of cryopreserved homograft aortic root replacement in
native valve endocarditis or prosthetic valve endocarditis associated with periannular abscess.
Methods: Between May 1986 and December 2007, 1163 patients with endocarditis were operated upon. Of
these, 221 patients (n ¼ 185 men, median age 55 years) had homograft aortic root replacement due to 99 cases
of native valve endocarditis (45%) and 122 of prosthetic valve endocarditis (55%). Perinannular abscess devel-
oped in 189 patients (86%), and aortoventricular dehiscence in 120 (63.5%) of them. Perioperative characteris-
tics, probability of survival, freedom from recurrence, and reoperation were analyzed. Follow-up (mean 5.2 0.4
years, maximum 18.4 years) was completed in 96.8% with a total of 1127 patient-years.
Results: Overall native valve endocarditis survival at 30 days and 1, 5, and 10 years was 83.8% 3.7%, 76.6%
 4.3%, 66.5%  4.9%, and 47.3%  5.6%, respectively, significantly better than for patients with prosthetic
valve endocarditis, who had a greater tendency toward abscess formation (P¼ .029). Thirty-one patients (14.0%)
required reoperation either for structural valve deterioration (n ¼ 19, 8.6%), with a greater tendency in patients
aged<40 years, or for recurrent endocarditis of the homograft (n ¼ 12, 5.4%). One-year reoperation mortality
rate was 16.1% (n ¼ 5).
Conclusions: Homograft aortic root replacement in active infective endocarditis with periannular abscess forma-
tion shows satisfactory early and long-term results with significantly better survival in native valve endocarditis
than prosthetic valve endocarditis. It is associated with a low recurrence rate, although the risk of structural valve
deterioration increases over time, especially in young patients, and reoperation remains a challenge. In our
institution, the homograft remains the preferred valve substitute in active infective endocarditis with periannular
abscess formation. (J Thorac Cardiovasc Surg 2010;139:665-73)Despite improvements in medical therapy, the incidence of
active infective endocarditis (AIE) and also the proportion
of approximately one-third of patients with endocarditis
requiring surgery because medical therapy has failed remain
unchanged.1 Surgical treatment for AIE still carries a high
mortality risk, and results of surgery depend on many vari-
ables, especially on whether the patients have native valve
endocarditis (NVE) or prosthetic valve endocarditis
(PVE),2 which is a very severe complication of valve
replacement and frequently associated with paravalvular
abscess formation,3-5 a destructive process that can progres-
sively and very rapidly lead to total aortic root destruction.
It has been our surgical strategy to treat active infective
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The Journal of Thoracic and Catissue, drainage and exclusion of myocardial abscesses
from the blood stream, repair with homologous material of
any cardiac defects caused by infection, and reconstruction
of the aortic root with a cryopreserved aortic homograft.6
This study was undertaken to review the 20-year experience
of homograft aortic root replacement (ARR) at the Deutsches
Herzzentrum Berlin and to reevaluate that strategy. The
goals of this retrospective study were: (1) to characterize the
demographic and clinical differences between patients with
NVE and patients with PVE and the nature of their endocar-
ditic disease; (2) to compare early and long-term results of
cryopreserved homograft ARR in these patients, especially
with regard to the survival in relation to periannular abscess
formation; (3) to determine the rates of reoperation due to ho-
mograft endocarditis recurrence; and finally (4) to analyze the
freedom from reoperation due to structural valve deterioration
(SVD) especially with regard to patient age at initial operation.PATIENTS AND METHODS
Patient Population
An overview of the patient population is given in Table 1. Between May
1986 and December 2007, a total of 1258 operations in 1163 patients with
AIE were performed at the Deutsches Herzzentrum Berlin, 925 (73.5%) of
them for NVE and 333 (26.5%) for PVE. Of these patients, 221 (n ¼ 185
men, median age 55, range 2–81 years) who had ARR with cryopreservedrdiovascular Surgery c Volume 139, Number 3 665
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D66Abbreviations and Acronyms6AIE ¼ aThective infective endocarditisARR ¼ aortic root replacement
NVE ¼ native valve endocarditis
PVE ¼ prosthetic valve endocarditis
SVD ¼ structural valve deteriorationhomograft due to 99 cases of NVE (45%) and 122 cases of PVE (55%)
were enrolled in the study. To exclude the effects of other endocarditic car-
diac pathologies on the outcome after homograft ARR, such as mitral valve
endocarditis, jet lesions, ventricular septal defects, or right-sided endocardi-
tis, only patients with isolated aortic valve and root endocarditis were
enrolled.
An overview of the microbiologic epidemiology and the differences be-
tween the patients with NVE and patients with PVE is given in Table 2. Of
the other patients (n ¼ 951), 426 were operated on due to isolated aortic
valve endocarditis; 280 due to mitral valve endocarditis, with 219 cases
of mitral valve replacement and 61 of mitral valve repair; 157 due to double
valve endocarditis; and 88 due to isolated (n ¼ 59) or combined (n ¼ 29)
right- and left-sided endocarditis.
Indications for Surgery
Table 3 presents an overview of the main operative indications during the
acute phase of AIE. In general, patients had several indications for surgery
during antibiotic treatment for AIE. The majority had to be operated on due
to progressive heart failure, suspected vegetations, recurrent septic embo-
lism, or therapy-resistant infections. In the NVE group, 67 (67.7%) patients
additionally showed aortic valve destruction. Early prosthetic infection
(<30 days) was found in 31 (25.4%) patients from the PVE group.
Surgical Technique of ARR
ARR is performed during standard cardiopulmonary bypass. Until 1999,
antegrade cold crystalloid cardioplegia with topical ice slush and with mild
systemic hypothermia (32 C) was used; later this was replaced by normo-
thermic blood cardioplegia.
After extensive debridement and complete removal of all macroscopi-
cally involved tissue of the diseased aortic root, the coronary ostia are
excised with a small rim of surrounding aortic tissue. This is followed by
intensive irrigation of the infected area with polyvidone-iodine solution.
If the aortic annulus is not destroyed by abscess, the proximal suture line
of the trimmed cryopreserved homograft conduit is placed using interrupted
4–0 polypropylene sutures preserved in polyvidone-iodine solution and
reinforced with glutaraldehyde-fixed equine pericardial pledgets from the
ventricle to the aorta at the aortic ventricular junction. In the presence of se-
vere aortic root endocarditis with extensive annular and subannular destruc-
tion by abscess formation, proximal homograft anastomosis is performed
with the lower margin of the abscess cavity in the left ventricular outflow
tract in the area of intact endocardial tissue. In the case of abscess aortoven-
tricular dehiscence, restoration of the structure and anchoring of the mitral
valve can be achieved by making use of the anterior mitral leaflet adhering
to the aortic homograft. The coronary ostia are reimplanted into the homo-
graft conduit using the button technique with 5–0 or 6–0 running monofil-
ament sutures. Finally, the distal anastomosis of the ascending aortic
segment of the homograft conduit, which is used for replacing the native
ascending aorta, is performed with 4–0 running polypropylene sutures.
Follow-up
Follow-up was completed by telephone contact with the patient, by an-
alyzing standardized mail questionnaires sent to the patients, by consultingJournal of Thoracic and Cardiovascular Surgthe population registry, and by contacting peripheral hospitals. In the NVE
group, 3 patients were lost to follow-up; follow-up was completed in 96.9%
of all cases with a median follow-up time of 6.5 years (range 0–17.7 years)
and 654.9 patient-years. In the PVE group, 4 patients were lost to follow-up;
follow-up was completed in 96.7% of all cases with a median follow-up
time of 2 years (range 0–18.4 years) and 471.5 patient-years. The signifi-
cantly shorter duration of median follow-up for the PVE group is due to
the fact that many patients from this group were operated on in recent years.
Statistical Analysis
Statistical analysis was performed using SPSS 12.0.1 for Windows. For
quantitative data, medians and ranges or means and standard error of the
mean were calculated. Qualitative data are reported as relative frequencies
and percentages. For comparison of different patient groups, Pearson’s c2
test or Student t test was used. Analysis of survival and freedom from end
points was performed according to the method of Kaplan-Meier. Standard
errors of the mean for Kaplan-Meier estimates were calculated by the Green-
wood formula. Comparison of survival in different patient groups was
performed using weighted log-rank tests. All the statistical analyses were
performed by an independent statistician.RESULTS
Demographic and Clinical Differences Between
Patients With NVE and Patients With PVE
Patients with PVE were significantly older (P  .001);
preoperatively, they showed renal insufficiency significantly
more often (P ¼ .024) and they more often developed ab-
scess formation (P ¼ .003) than patients with NVE. By an-
alyzing the extent of the abscess formation, it was found that
patients with PVE more often showed severe aortic root de-
struction with aortic-ventricular dehiscence compared with
patients with NVE (P  .001), in whom predominantly
well-circumscribed and localized abscess formation was
found (Table 1). Patients with PVE showed significantly
more infection caused by Staphylococci (P ¼ .016) com-
pared with the patients with NVE, in whom streptococcal
infection was the main finding (P  .001; Table 2).
In the quantity of preoperative septic embolization, there
was no difference between the groups, but analyzing the
localization, the incidence of skin embolism was higher in
patients with PVE (P ¼ .016).
By analyzing the preoperative status, it was found that
a large proportion of patients were referred to our depart-
ment with advanced endocarditis and in a condition of
cardiac and pulmonary decompensation. No significant dif-
ferences were found in the degree of fever (P ¼ .955) and
septic shock (P ¼ .402), cardiac decompensation (P ¼
.258) leading to high-dose catecholamines (P ¼ .711), or
pulmonary edema (P ¼ .143) with the need of intubation
(P ¼ .359) between the 2 groups. In terms of the urgency
of operation, both groups showed a high percentage of
patients having an emergency or urgent procedure (P ¼
.412) with similar numbers of days from diagnosis until
operation (P ¼ .891).
Gender (P ¼ .680), diabetes (P ¼ .198), chronic obstruc-
tive pulmonary disease (P ¼ .144), and intravenous drugery c March 2010
TABLE 1. Demographic and clinical differences between patients
with NVE and patients with PVE (May 1986–December 2007)
NVE PVE P value
Patients with AIE .680
Men 84 (84.8%) 101 (82.8%)
Women 15 (15.2%) 21 (17.2%)
Total 99 122
Age (y) <.001
Median 50.0 60.0
Mean age 47.4  14.8 57.3  14.8
Range 2–76 18–81
Age groups (y) <.001
<40 27 19
40–60 54 43
>60 18 60
Preoperative status
Cardiac shock 5 (5.1%) 11 (9.0%) .258
High-dose catecholamines 24 (24.2%) 27 (22.1%) .711
Pulmonary edema 25 (25.2%) 21 (17.2%) .143
Intubation 21 (21.2%) 20 (16.4%) .359
Septic shock 8 (8.1%) 14 (11.5%) .402
Renal insufficiency 24 (24.2%) 47 (38.5%) .024
Dialysis 4 (4.0%) 11 (9.0%) .144
Persistent fever 46 (46.4%) 57 (46.7%) .955
Diabetes 18 (18.2%) 31 (25.4%) .198
COPD 4 (4.0%) 11 (9.0%) .144
Hypertension 17 (17.2%) 54 (44.3%) <.001
Intravenous drug abuse 5 (5.1%) 5 (4.0%) .217
Alcohol abuse 21 (21.2%) 7 (5.7%) <.001
Septic embolization
Quantity .348
One 22 (22.2%) 23 (18.9%)
Multiple 12 (12.1%) 9 (7.4%)
Localization
Cerebral 14 (14.1%) 20 (16.4%) .644
Lung 3 (3.0%) 1 (0.8%) .220
Spleen 10 (8.2%) 9 (9.1%) .814
Kidney 7 (7.1%) 4 (3.3%) .197
Eye 3 (3.0%) 1 (0.8%) .220
Skin 3 (2.5%) 10 (10.1%) .016
Aortic root abscess formation .003
No 22 (22.2%) 10 (8.2%)
Yes 77 (77.8%) 112 (91.8%)
Extent of abscess formation <.001
Localized abscess formation 42 (42.4%) 27 (22.1%)
Aortic-ventricular dehiscence 35 (35.4%) 85 (69.7%)
Operation performed as .412
Elective 6 (6.1%) 11 (9.0%)
Urgent 69 (69.7%) 91 (74.6%)
Emergency 24 (24.2%) 20 (16.4%)
Days until operation .891
Median (range) 25 (2–161) 29.5 (2–133)
Mean 40.0  3.5 38.0  2.7
Follow-up (y) .029
Completed 96.9% 96.7%
Median 6.5 2
Mean 6.6  0.5 3.8  0.4
TABLE 1. Continued
NVE PVE P value
Range 0–17.7 0–18.4
Patient-years 654.9 471.5
NVE, Native valve endocarditis; PVE, prosthetic valve endocarditis; AIE, active infec-
tive endocarditis; COPD, chronic obstructive pulmonary disease. Significant differ-
ences are in italic.
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parison, whereas hypertension (P  .001) was significantly
higher in the PVE group and alcohol abuse in the patients
with NVE (P  .001).A
C
DOverall Survival, Early ( 30 Days) and Late
Mortality
The overall survival curves after homograft ARR in pa-
tients with NVE and patients with PVE are given in Figure 1.
We found a highly significant better survival for the NVE
compared with the PVE group. The 30-day and 1-, 5-, and
10-year survivals for the NVE group were 83.8% 
3.7%, 76.6%  4.3%, 66.5%  4.9%, and 47.3% 
5.6%, compared with 74.6%  3.9%, 67.1%  4.2%,
48.1%  4.9%, and 35.0%  5.4% for the PVE group,
respectively (P ¼ .029).
Analysis of the survival curve showed a particularly clear
difference between the 2 groups in the first 30 days. In the
NVE group (n ¼ 99), there were 16 early deaths (30
days) resulting in an early mortality rate of 16.1%. Of these,
1 was an intraoperative death due to myocardial failure
(6.2%), 1 patient died of hemorrhagic shock in the first post-
operative week (6.2%), 9 patients died of septic multiorgan
failure (56.3%), 4 patients died of myocardial failure
(25.0%), and 1 other died of other causes (6.2%).
In comparison, in the PVE group (n ¼ 122) there were 31
early deaths (30 days) resulting in an early mortality rate of
25.4%. There were 9 (29.1%) intraoperative deaths: 6 pa-
tients died of myocardial failure and 3 patients died of septic
multiorgan failure operated on as a last resort treatment. The
causes of the other 22 early deaths in this group were septic
multiorgan failure in 14 (45.2%), myocardial failure in 6
(19.3%), cerebral abscess formation in 1 (3.2%), and exces-
sive esophageal bleeding in 1 other case (3.2%).
Analysis of early mortality in various subgroups of pa-
tients showed that patients with persistent fever despite anti-
biotic treatment (31.4%), patients requiring high doses of
catecholamines (47.1%), patients on ventilation (53.7%),
and those who arrived at our hospital in septic shock
(72.7%) were highly exposed.
Comparison of late mortality (30 days to 1 year) showed
similar rates in both groups. In the NVE group, the late
mortality rate was 7.0%, with 7 late deaths due to septic
multiorgan failure in 3, myocardial failure in 2, and other
causes in 2 patients, compared with late mortality rate ofrdiovascular Surgery c Volume 139, Number 3 667
TABLE 2. Microbiologic epidemiology: Differences between patients
with native valve endocarditis and patients with prosthetic valve
endocarditis (May 1986–December 2007)
NVE PVE P value
Staphylococci 26 (26.2%) 51 (41.8%) .016
S aureus 19 (19.2%) 27 (22.1%) .593
S coagulase-
negative
4 (4.0%) 8 (6.6%) —
S epidermidis 2 (2.0%) 8 (6.6%) —
MRSA — 4 (3.3%) —
S general 1 (1.0%) 4 (3.3%) —
Streptococci 41 (41.4%) 21 (17.2%) <.001
S general 21 (21.2%) 12 (9.8%)
S viridans 17 (17.2%) 6 (4.9%)
S ß-hemolysis 2 (2.0%) 2 (1.6%)
S epidermidis 1 (1.0%) 1 (0.8%)
Enterococcus 9 (9.1%) 16 (13.1%) .348
Culture-negative 17 (17.1%) 21 (17.2%) .994
Candida 1 (1.0%) 1 (0.8%) —
Pseudomonas — 1 (0.8%) —
Others 2 (2.0%) 4 (3.3%) —
Unknown 3 (3.0%) 7 (5.7%) —
NVE, Native valve endocarditis; PVE, prosthetic valve endocarditis; MRSA, methicil-
lin-resistant Staphylococcus aureus.
TABLE 3. Main indications for surgery
Indication NVE PVE
Progressive heart failure 80 (80.8%) 86 (70.5%)
þvegetations 66 (66.6%) 35 (28.7%)
þrecurrent septic embolisms 24 (24.2%) 21 (17.2%)
þ therapy-resistant septic infections 16 (16.1%) 11 (9.1%)
Vegetations 81 (81.8%) 52 (42.6%)
Recurrent septic embolism 34 (34.3%) 32 (26.2%)
Therapy-resistant septic infection 25 (25.2%) 39 (31.9%)
Aortic valve destruction 67 (67.7%) 20 (16.4%)
Early prosthetic infection (<30 d) — 31 (25.4%)
NVE, Native valve endocarditis; PVE, prosthetic valve endocarditis.
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tiorgan failure in 6, myocardial failure in 1, and other causes
in 2 patients.
In addition, the comparison of the 426 patients who were
operated on without homograft implantation due to isolated
aortic valve endocarditis (NVE¼ 358 patients, PVE¼ 68 pa-
tients) showed the following survival rates: 81.2% 2.1%,
70.0%  2.4%, 57.7%  2.8%, 44.7%  3.2%, and
24.4%  4.1% for 30-day and 1-, 5-, 10-, and 15-year sur-
vivals in the NVE group compared with 80.9%  4.8%,
69.1%  5.6%, 52.5%  6.8% for 30-day and 1- and 5-
year survivals in the PVE group, respectively (P ¼ .626).Survival in Relation to Abscess Formation
The comparison of the patient subgroups having abscess
formation revealed a highly significant better survival of
the NVE compared with the PVE group: the 30-day and 1-,
5-, 10-, and 15-year survivals for the NVE group were
83.0%  4.3%, 73.8%  5.0%, 65.0%  5.6%, 47.7%
 6.5%, and 29.8%  8.7%, respectively, compared with
74.1%  4.1%, 66.8%  4.5%, 48.5%  5.1%, 36.7%
 5.5%, and 31.0%  6.5% in the PVE group (P ¼ .042).
Analyzing survival after homograft ARR in relation to the
extent of abscess formation, there was a nonsignificant trend
toward better survival in patients with localized abscess (n¼
69) compared with those with severe aortic root destruction
leading to aortoventricular dehiscence (n¼ 120): the 30-day
and 1-, 5-, and 10-year survivals for patients with localized
abscess were 84.0%  4.4%, 73.8%  5.3%, 61.9% 
6.1%, and 44.8%  7.2%, respectively, in comparison668 The Journal of Thoracic and Cardiovascular Surgwith 74.1%  4.0%, 67.3%  4.3%, 51.8%  4.8%,
and 39.4%  0.5% in patients with aortoventricular dehis-
cence (P ¼ .091; Figure 2).Freedom From Reoperation Due to All Events
A total of 31 of 221 patients (14.0%) had either reinfection
(n ¼ 12, 6 patients with NVE and 6 patients with PVE) or
SVD (n ¼ 19, 11 patients with NVE and 8 patients with
PVE) leading to reoperation following homograft ARR.
Analysis of the freedom from reoperation due to all events
after homograft ARR in patients with NVE and patients with
PVE showed no significant differences between the 2
groups: the 30-day and 1-, 5-, 10-, and 15-year freedom
from reoperation was 97.6%  1.2%, 91.3%  3.2%,
83.7%  4.4%, 77.6%  5.3%, and 73.9%  6.2% for
the patients with NVE in comparison to 98.0%  1.4%,
89.7%  3.3%, 84.2%  4.4%, and 79.3%  5.8% for
10 years for patients with PVE (P ¼ .957).Freedom From Reoperation Due to Reinfection
A total of 12 of 221 patients (5.4%) had reinfection lead-
ing to reoperation following homograft ARR in patients with
NVE (n¼ 6) and patients with PVE (n¼ 6), resulting in 10-
year freedom from reoperation of 92.9%  3.2% and
92.1%  2.5%, respectively (P ¼ .913; Figure 3). Preoper-
atively, all 12 patients showed aortic root abscess formation.
Of the 6 cases of reinfection in the NVE group (6.0%),
there were 2 early reinfections ( 60 days, 2.0%), 2 late re-
infections (60 days to 1 year, 2.0%), and 2 de novo infec-
tions 6.7 and 16.8 years after the first operation (2.0%).
On reoperation, 1 patient received a mechanical valve, 2
a bioprosthesis, and 3 an aortic homograft. There was no
intraoperative or cardiac-related death. One patient died on
postoperative day 130, resulting in a 1-year reoperation mor-
tality rate of 16.6% (1/6) for the NVE group.
The 6 reinfections of the PVE group (4.9%) were 3 early
reinfections ( 60 days, 2.5%), 2 late reinfections (1.6%),
and 1 de novo infection 2.8 years after the first operation
(0.8%). On reoperation, 2 patients received mechanical
valves, 1 received a bioprosthesis, and 3 patients receivedery c March 2010
FIGURE 1. Survival after homograft aortic root replacement in native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE).
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Dan aortic homograft. There was no intraoperative or cardiac-
related death, and all patients survived the first year.
In summary, of the 12 patients reoperated upon due to
reinfection, there was no intraoperative or cardiac-related
death and 1 patient from the NVE group died on postopera-
tive day 130, resulting in 1-year reoperation survival of
91.6% for this collective (11/12).
Freedom From Reoperation Due to SVD
SVD developed in 19 of 221 patients (8.6%), leading to
reoperation following homograft ARR: 11 patients with
NVE and 8 patients with PVE. Figure 4, A shows the
freedom from reoperation due to SVD with no significant
differences between the 2 groups: the 30-day and 1-, 5-,FIGURE 2. Survival after homograft aortic root replacement. Ao
The Journal of Thoracic and Caand 10-year freedom from reoperation was 98.8%  1.2%,
96.3% 2.1%, 88.8% 3.8%, and 85.0% 4.5% for pa-
tients with NVE in comparison with 99.1%  0.9%, 94.4%
 2.5%, 92.0%  3.3%, and 86.0%  5.2% for patients
with PVE (P ¼ .910).
In the NVE group, of the 11 of 99 patients (1.68%/
patient-year), 3 had to be reoperated on due to early homo-
graft valve insufficiency (3.0%) at a mean of 78 days
(30–140 days) after the first operation. Four patients had ho-
mograft degeneration leading to severe aortic insufficiency
(4.0%) and were reoperated on after a mean of 3.3 years
(1.5–6.2 years). Another 4 patients had homograft calcifica-
tion with severe aortic stenosis (4%) leading to reoperation
after a mean of 5.9 years (1.8–10.9 years). On reoperation, 9rtoventricular dehiscence versus localized abscess formation.
rdiovascular Surgery c Volume 139, Number 3 669
FIGURE 3. Freedom from reoperation due to reinfection after homograft aortic root replacement. NVE, Native valve endocarditis; PVE, prosthetic valve
endocarditis.
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in 1, a 2-year-old child, a Ross operation was performed.
There was no intraoperative or cardiac-related death. Two
patients died, 1 on postoperative day 14 due to septic multi-
organ failure and the other on postoperative day 64 due to
pulmonary failure, resulting in a 1-year reoperation mortal-
ity rate of 18.1% (2/11) for the NVE group.
In the PVE group, of the 8 of 122 patients (1.7%/patient-
year), 5 had to be reoperated upon within 1 year due to early
homograft valve insufficiency or paravalvular leakage
(4.1%) at a mean of 122 days (1–345 days) after the first
operation.FIGURE 4. A, Freedom from reoperation due to structural valve deterioration af
prosthetic valve endocarditis (PVE). B, Freedom from reoperation due to stru
operation.
670 The Journal of Thoracic and Cardiovascular SurgThree patients had homograft degeneration (2.4%) lead-
ing to severe aortic insufficiency in 1 and severe aortic ste-
nosis in 2 and were reoperated on at a mean of 5.4 years
(4.2–6.8 years). On reoperation, 3 patients were given me-
chanical valves, 3 received a bioprosthesis, and 2 received
an aortic homograft. Two patients died from cardiac failure
(on the postoperative days 1 and 209), and the 1-year reop-
eration mortality rate was 25.0% for this group.
In summary, of the 19 patients reoperated upon due to
SVD, 4 patients died within 1 year (mean 72 days, range
1–209 days), resulting in a 1-year reoperation survival rate
of 78.9% for this collective (15/19).ter homograft aortic root replacement in native valve endocarditis (NVE) and
ctural valve deterioration after homograft aortic root replacement. Age at
ery c March 2010
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DFreedom From Reoperation Due to SVD According
to Patient Age at Initial Operation
Figure 4, B shows the freedom from reoperation due to
SVD in 3 patient age groups (<40 years, 40–60 years,>60
years) at the time of initial operation: the 30-day and 1-, 5-,
and 10-year freedom from reoperation for the<40 years
group (n ¼ 46 patients) was 97.7%  2.3%, 91.5% 
4.7%, 79.8%  7.7%, and 79.8%  7.7%. In comparison,
the rates for the 40- to 60-year group (n ¼ 97 patients) were
98.6%  1.4%, 95.6%  2.5%, 91.8%  3.5%, and
84.4% 5.2% and for the>60-year group (n¼ 78 patients),
100%, 96.5%  2.4%, 92.9%  4.2%, and 88.7%  58.
The comparison showed no significant difference between
the<40-year group and the 40- to 60-year group (P ¼ .141)
or between the 40- to 60-year and the>60-year groups (P¼
.711). Comparing the <40-year group and the >60-year
groups, there was a higher tendency toward reoperation for
the younger group (P¼ .088), which did not reach statistical
significance, likely due to the low number of patients at risk
for the period of 10 to 15 years postoperatively.
DISCUSSION
Our study presents 20-year single-center results in a group
of high-risk patients with active infective NVE and PVE
having ARR with cryopreserved homografts and compares
the outcome of these patients. The results of our study con-
firm previous reports that documented worse outcomes of
patients with PVE compared with patients with NVE in
regard to higher operative mortality and poorer long-term
survival.7-9
In our study, analysis of the survival curve shows a par-
ticularly clear difference between the 2 groups in the first
30 days. The argument can be forwarded that the better
results in the NVE group are related to the fact that the pa-
tients with PVE in general had more advanced endocarditis
and were more critically ill. As shown in our series, patients
with PVE were not only significantly older but preopera-
tively they had a significantly higher prevalence of renal
insufficiency and infection caused by Staphylococci.
They more often had abscess formation with severe aortic
root destruction leading to a higher rate of aortic-ventricu-
lar dehiscence than the patients with NVE (69.7% vs
35.4%). Each of these factors increases the clinical vari-
ability and complexity of AIE and may represent an addi-
tional possible explanation for much of the morbidity and
mortality in the PVE group.3,5 Our study confirms previous
reports that documented the association of periannular
abscess complications with increased mortality and the
need of surgery in almost all patients,2,5 underlined by
recently published data by David and colleagues.10 They
demonstrated that surgery for active endocarditis with para-
valvular abscess was associated with high operative mortal-
ity, particularly in patients in shock and with abscess
formation on both mitral and aortic annuli.The Journal of Thoracic and CaDespite high operative mortality and morbidity, the long-
term survival was satisfactory considering how sick the
patients were prior to surgery and the complexity of the
operative procedures, similar to published data from Toronto
and Stanford University.7,11 For the risk stratification and
survival in our study, it has to be taken into consideration
that our hospital is a referral surgical center receiving patients
who have already been treated medically elsewhere and we
had no input regarding the medical management. They
were referred for surgery only after medical therapy failed.
The low early reinfection rate and the excellent long-term
freedom from reinfection without any significant differences
between the NVE and PVE groups reported in this study
document the outstanding role of the homograft in the treat-
ment and eradication of AIE and confirm the findings of pre-
vious publications.10,12 Additionally, in severe destructive
endocarditis with aortoventricular dehiscence, restoration
of the structure can be achieved by making use of the mus-
cular cuff of the soft annulus and of the anterior mitral leaflet
adhering to the aortic homograft.
However, several additional aspects have to be empha-
sized in this analysis. The goals of aggressive surgical treat-
ment for acute aortic root endocarditis are radical excision of
all infected tissue, drainage and exclusion of myocardial ab-
scesses from the bloodstream, repair of any cardiac defects
caused by infection, and reconstruction of the aortic root
with the aim of placing a competent valve and preventing re-
current infection. We believe our lower risk was due both to
these surgical principles and to the use of homografts, which
by their natural biocompatibility are resistant to infection.13
In the evaluation of results of homograft series, one must
clearly identify the incidence of AIE and abscess reported
in the study population and the surgical techniques used.
Kaya and associates14 reported only 4 cases of homograft
endocarditis in 213 patients (1.9%) having ARR with a cry-
opreserved aortic homograft, but in their series only 125 pa-
tients (58.7%) had clinical evidence of AIE. O’Brien and
colleagues12 reported only 2 cases of early endocarditis in
1022 patients (0.19%) and freedom from late infection (34
patients) at 20 years was 89%, but endocarditis was reported
as the preoperative indication in only 92 patients (9.0%) in
their series compared with our study with 221 patients with
endocarditis, 189 of them (85.5%) with abscess formation.
David and coworkers10 reported on 135 patients with AIE
(n ¼ 69 NVE, 66 PVE) and paravalvular abscess. In their
study, there were 16 episodes of recurrent endocarditis in
15 patients (11.1%) and the freedom from recurrent endo-
carditis was 82.4% at 15 years, but only 14 patients received
an aortic homograft at the primary operation. Excellent re-
sults are reported by Sabik and colleagues13 from Cleveland
Clinic, who analyzed their experience of homograft ARR in
103 consecutive patients with prosthetic aortic valve endo-
carditis presenting with an aortic root abscess in 78% of
the cases. Four patients (3.8%) had recurrent endocarditis.rdiovascular Surgery c Volume 139, Number 3 671
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from that found in other studies and peaked at 9 months after
operation; freedom from recurrent endocarditis at 5 and 10
years was 95%.
Reinfection may be caused not only by virulent organisms
but also by surgical factors such as inadequate debridement
of necrotic tissues and the abscess cavity prior to exclusion
from the circulation. In our study, all 5 patients in whom early
recurrent endocarditis developed had deeply invasive and
destructive infections, and the offending microorganisms
were the same as in the first infection. Because of its com-
plexity, homograft reoperation remains a challenge. In our
study, 1 of 12 patients reoperated upon due to homograft en-
docarditis died on postoperative day 130, resulting in a low
hospital mortality, which varies greatly in the literature.14,15
The influence of the age of the recipient on the long-term
durability of the homograft has been reported previously by
numerous studies showing that younger patient age is the
most important predictor of SVD.9 In our study, the compar-
ison between the<40-year group and the>60-year group
showed a greater tendency for reoperation due to SVD for
the younger group, which did not reach statistical signifi-
cance because of the low number of patients at risk in the
long-term period (P¼ .088). Using the Weibull model to cal-
culate long-term freedom from reoperation, which is based
on the assumption that the risk of SVD increases with time
and therefore that the estimates are still hypothetical, Takken-
berg and colleagues16 demonstrated that median time to reop-
eration for SVD varies from 23 years in a 65-year-old patient
down to approximately 12 years in a 25-year-old patient.16
Because of these data, the complexity of the operation, and
the controversial discussion of the risk of recurrent endocar-
ditis for mechanical and bioprosthesis reported in the litera-
ture, the superiority of the homograft in the treatment of
AIE has been questioned. The best type of prosthesis for im-
plantation in patients with native and prosthetic AIE is a mat-
ter of controversial discussion in the literature. However, the
few studies that compare mechanical and biological prosthe-
ses are limited in terms of the numbers of patients, and the
study populations are mostly not comparable with each other.
In the study by Moon and colleagues11 of patients with native
and prosthetic endocarditis, the operative mortality, the sur-
vival rate, and the rate of freedom from reoperation were in-
dependent of whether a mechanical or a biological valve was
implanted. Leyh and associates17 published a study that
found the 1- and 5-year survival rates in patients with acute
aortic valve prosthetic endocarditis who received an ARR
to be independent of whether a homograft or a composite
prosthesis was used. None of these patients (n ¼ 24) had to
be reoperated on because of reinfection. Many have treated
this problem with prosthetic root replacement, using either
mechanical or tissue valves. Additionally, excellent results
have been reported in patients with AIE by using the Ross
procedure, although the number of patients is still low.11,18,19672 The Journal of Thoracic and Cardiovascular SurgStudy Limitations
The present study is retrospective. Clinical end points
such as exercise capacity and echocardiographic hemody-
namic control could not be assessed. There is a natural
bias in the clinical assessment of the 2 patient groups.CONCLUSIONS
Homograft ARR in AIE with periannular abscess forma-
tion shows satisfactory early and long-term results with sig-
nificantly better survival in NVE than PVE. It enables
complete eradication of the infection by radical excision,
replacement of all infected tissue of the aortic annulus and
aortic root, and reconstruction of the left ventricular outflow
tract, especially in severe destructive endocarditis with aor-
toventricular dehiscence. Homograft ARR is associated with
a low endocarditis recurrence rate. The risk of SVD
increases over time, especially in young patients, and reop-
eration remains a challenge. Even more than 45 years after
its clinical introduction,20 homograft ARR remains the
preferred valve substitute in AIE with periannular abscess
formation in our institution.
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